A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?

Author(s): Barbara Cacciari*, Giampiero Spalluto, Stephanie Federico

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 18 , Issue 14 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


In the past decades, many efforts were undertaken to develop ligands for the adenosine receptors, with the purpose to individuate agonists and antagonists affinity and selectivity for each subtypes, namely A1, A2A, A2B, and A3. These intense studies allowed a deeper knowledge of the nature and, moreover, of the pathophysiological roles of all the adenosine receptor subtypes. In particular, the involvement of the A2A adenosine receptor subtype in some physiological mechanisms in the brain, that could be related to important diseases such as the Parkinson’s disease, encouraged the research in this field. Particular attention was given to the antagonists endowed with high affinity and selectivity since they could have a real employment in the treatment of Parkinson’s disease, and some compounds, such as istradefylline, preladenant and tozadenant, are already studied in clinical trials. Actually, the role of A2A antagonists in Parkinson’s disease is becoming contradictory due to contrasting results in the last studies, but, at the same time, new possible employments are emerging for this class of antagonists in cancer pathologies as much interesting to legitimate further efforts in the research of A2A ligands.

Keywords: A2A antagonists, adenosine, Parkinson’s disease, cancer, heterotetramers, immunosuppression.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [1168 - 1174]
Pages: 7
DOI: 10.2174/1389557518666180423113051
Price: $65

Article Metrics

PDF: 103
HTML: 14
PRC: 1